A study published in 2018 by Schmitz et al, who evaluated 574 DLBCL patients using exome and transcriptome sequencing on biopsy samples, identified four genetic DLBCL subtypes: subtype BN2, based on BCL6 fusions and NOTCH2 mutations, subtype EZB, based on EZH2 mutations and BCL2 translocations, subtype MCD, based on the co-expression of MYD88L265P and CD79B mutations, and N1 subtype based on the presence of NOTCH1 mutation. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.